Co-Authors
This is a "connection" page, showing publications co-authored by JIUN-KAE JACK LEE and IGNACIO IVAN WISTUBA.
Connection Strength
2.579
-
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014 Jul 15; 20(14):3849-61.
Score: 0.120
-
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92.
Score: 0.119
-
Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5.
Score: 0.118
-
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201.
Score: 0.117
-
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6556-65.
Score: 0.115
-
G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1747-1754.
Score: 0.108
-
Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila). 2013 Jan; 6(1):8-17.
Score: 0.108
-
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012 May; 7(5):833-40.
Score: 0.104
-
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011 Aug 15; 71(16):5512-21.
Score: 0.098
-
Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011 Jun; 4(6):779-82.
Score: 0.098
-
Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-?) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer. 2011 Nov; 12(6):369-74.
Score: 0.097
-
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011 Apr 15; 17(8):2434-43.
Score: 0.095
-
Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res (Phila). 2010 Jun; 3(6):738-44.
Score: 0.091
-
Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res. 2010 Jan 01; 16(1):34-44.
Score: 0.088
-
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009 Sep 01; 15(17):5359-68.
Score: 0.086
-
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006 Dec 01; 107(11):2637-46.
Score: 0.072
-
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
Score: 0.032
-
Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer. J Biol Chem. 2015 Mar 20; 290(12):7345-59.
Score: 0.031
-
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9.
Score: 0.031
-
Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014 May; 9(5):675-84.
Score: 0.030
-
Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014 May; 15(3):213-21.
Score: 0.029
-
Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 01; 20(7):1946-54.
Score: 0.029
-
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.
Score: 0.029
-
ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3383-95.
Score: 0.028
-
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
Score: 0.028
-
Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.
Score: 0.028
-
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8.
Score: 0.027
-
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 2013 Jan 15; 73(2):571-82.
Score: 0.027
-
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
Score: 0.027
-
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
Score: 0.027
-
Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20; 30(27):3345-52.
Score: 0.027
-
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012 May; 7(5):825-32.
Score: 0.026
-
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833.
Score: 0.026
-
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer. 2012 Aug 15; 118(16):3993-4003.
Score: 0.026
-
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
Score: 0.025
-
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
Score: 0.025
-
Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Jun 01; 118(11):2889-99.
Score: 0.025
-
Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012 May 01; 118(9):2454-65.
Score: 0.025
-
The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila). 2011 Jul; 4(7):962-72.
Score: 0.025
-
Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One. 2011; 6(6):e21428.
Score: 0.025
-
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
Score: 0.024
-
Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology. 2011 Jun; 152(6):2164-73.
Score: 0.024
-
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85.
Score: 0.024
-
A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res. 2011 Mar 15; 17(6):1490-501.
Score: 0.024
-
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
Score: 0.023
-
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 2010 May 06; 29(18):2616-27.
Score: 0.022
-
Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila). 2010 Feb; 3(2):148-59.
Score: 0.022
-
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.
Score: 0.022
-
Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res. 2009 Sep 15; 69(18):7439-48.
Score: 0.022
-
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009 Aug; 2(8):702-11.
Score: 0.022
-
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6014-22.
Score: 0.020
-
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72.
Score: 0.019
-
Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res. 2006 Dec 01; 66(23):11194-206.
Score: 0.018